IsoPlexis' T cell and other immune cell polyfunctional cytokine responses have been able to predict a variety of responses in human and mice studies throughout cancer immunology and infectious disease. Also, Moriya Tsuji, a professor of medicine at Columbia, has published vaccine studies of malaria and also in oncology that used IsoPlexis' single-cell functional proteomics platform.

Columbia and IsoPlexis plan to detect and discover critical components in the overall cellular response to COVID-19, which can then be used to create therapies.

Sharing is caring: Why COVID-19 vaccine manufacturers must collaborate
Sharing knowledge between competitors will be key for establishing the manufacturing capacity needed to produce billions of COVID-19 vaccines in coming...

U.S. to pay $1.5B for Moderna's COVID-19 vaccine
The U.S. government awarded a maximum $1.525 billion contract to Moderna to secure 100 million doses of its messenger RNA COVID-19 vaccine.

Biosimulation can mitigate risk of COVID-19 drug development
Drug development can be an expensive and tedious process. Add in the urgency of the COVID-19 pandemic, and you have a recipe for frustration. Biosimulation...

COVID-19 vaccine based on peptide nanofibers shows promise
A new technology platform using self-assembling peptide nanofibers tagged with antibodies can be an effective SARS-CoV-2 vaccine, according to a proof-of-concept...

New COVID-19 vaccine candidate leverages earlier research
Could vaccine platforms developed for previous coronaviruses be converted to address the current COVID-19 pandemic? An August 5 report in Nature...